Литература

Поставить закладку

Brown K.Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen// Expert Opin Drug Saf. -2002.-Vol.1.-p.253-267.
Carder PJ, Shaaban A, Alizadeh Y, et al. Screen-detected pleomorphic lobular car- cinoma in situ (PLCIS): risk of concur- rent invasive malignancy following a core biopsy diagnosis//Histopathology. -2010.-Vol.57.-p.472-478.
Chuba PJ, Hamre MR, Yap J, et al. Bilateral risk for subsequent breast cancer after lobu- lar carcinoma-in-situ: analysis of surveil- lance, epidemiology, and end results data//J Clin Oncol.- 2005.-Vol.23.-p.5534-5541.
Correa C, McGale P, Taylor C, et al: Overview of the randomized trials of ra- diotherapy in ductal carcinoma in situ of the breast// J Natl Cancer Inst Monogr.- 2010.-Vol. 41.-p.162-177/
Fisher B., Constantino J.P, Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Sur- gical Adjuvant Breast and Bowel Project P-1 Study// J. Natl. Cancer Inst.- 1998.- Vol. 90.- p.1371-1388.
Fisher B., Dignam J., Wolmark N., et al. Tamoxifen in treatment of intraductal breast cancer: NSABP B-24 randomized controlled trial. // Lancet.- 1999.- Vol. 353.- p.1993-2000.
Fisher E.R., Dignam J., Tan-Chiu E., Costantino J. Pathologic findings from the national surgical adjuvant breast project (NSABP) eight-year update of Protocol B-17 // Cancer.- 1999.- Vol. 86.- N 3.- p.429-438.
Flanagan M.R., Rendi M.H., Calhoun K.E., Anderson B.O., Javid S.H. Pleo- morphic Lobular Carcinoma In Situ: Ra- diologic-Pathologic Features and Clinical Management//Ann Surg Oncol.-2015.- Vol.22.-p.4263-4269.
Forbes J.F., Sestak I., Howell A., Bonanni B., Bundred N., Levy C., von Minckwitz G., Eiermann W., Neven P., Stierer M., Holcombe C., Coleman R.E., Jones L., Ellis I., Cuzick J.; IBIS-II investigators. Anastrozole versus tamoxifen for the pre- vention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, ran- domised controlled trial//Lancet.-2016.- Vol.387.-p.866-873.
Goyal S., Vicini F., Beitsch D. et al. Duc- tal carcinoma in situ treated with breast-conserving surgery and accelerated partial breast irradiation: comparison of the Mammosite Registry trial with Inter- group Study E5194// Cancer.- 2011.- Vol. 117 – P.1149-1155.
Guidi AJ, Connolly JL, Harris JR, et al: The relationship between shaved margin and inked margin status in breast excision speci- mens// Cancer.-1997.-Vol. 79.-p.1568-1573.
Houghton J., George W.D., Cuzick J., Duggan C., Fentiman I.S., Spittle M. Ra- diotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled tri- al. // Lancet. – 2003. – Vol. 1362(9378).- P.95-102.
Hughes L.L., Wang M., Page D.L. et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncolo- gy Group// J. Clin. Oncol.- 2009.- Vol. 27.- P. 5319-5324.
Kim K., Jung S.Y., Shin K.H., Kim J.H., Han W., Lee H.B., Huh S.J., Choi D.H., Park W., Ahn S.D., Kim S.S., Kim J.H., Suh C.O., Kim Y.B., Kim I.A., Kim S., Kim Y.J. Recurrence outcomes after omission of postoperative radiotherapy following breast-conserving surgery for ductal carcinoma in situ of the breast: a multicenter, retrospective study in Korea (KROG 16-02)// Cancer Res Treat. -2017.-Vol.162.-p.77-83.
Lagios M.D. Heterogeneity of ductal carcinoma in situ: Relationship of grade and subtype analysis to local recurrence and risk of invasive transformation. // Cancer Letters. -1995. -Vol. 90 - p.97- 102.
Lagios M.D. Lagios experience // Silver- stein M.J. (Ed.) Ductal carcinoma in situ of the breast.-Baltimore: Williams and Wilkins. - 1997. - p.363-364.
Li CI, Anderson BO, Daling JR, Moe RE. Changing incidence of lobular carci- noma in situ of the breast//Breast Cancer Res Treat. -2002.-Vol.75.-p.259-268.
Margolese R.G., Cecchini R.S., Julian T.B., et al: Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): A ran- domised, double-blind, phase 3 clinical trial//Lancet.-2016.-Vol. 387.-p.849-56.
Marinovich ML, Azizi L, Macaskill P, et al: The association of surgical margins and local recurrence in women with ductal carcinoma in situ treated with breast-con- serving therapy: A meta-analysis//Ann Surg Oncol.-2016.-Vol.23.-p. 3811-3821/
Morrow M., Van Zee., Solin L. et al. So- ciety of Surgical Oncology–American So- ciety for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Con- serving Surgery With Whole-Breast Irradi- ation in Ductal Carcinoma In Situ// J. Clin. Oncol. - 2016. Vol. 34. – pp. 4040 – 4046.
Motwani S.B., Goyal S., Moran M.S. et al. Ductal carcinoma in situ treated with breast-conserving surgery and radiothera- py: a comparison with ECOG Study 5194// Cancer.- 2011.- Vol. 117. – P. 1156-1162.
Rosen P.P. Axillary lymph node metasta- ses in patients with occult noninvasive breast carcinoma//Cancer.-1980.-Vol. 46.-P. 1289-1306.
Silverstein MJ.Ductal carcinoma in situ of the breast. //Annu. Rev. Med.- 2000.- Vol.51.- P.17-32.
Solin LJ, Gray R, Hughes LL, et al: Sur- gical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study//J Clin Oncol.-Vol. 33.-p.3938- 3944.
Timbrell S., Al-Himdani S., Shaw O., Tan K., Morris J., Bundred N. Comparison of Local Recurrence After Simple and Skin-Sparing Mastectomy Performed in Patients with Ductal Carcinoma In Situ.// Ann Surg Oncol.-2017.- Vol.24.-p.1071-1076.
Van Zee KJ, Subhedar P, Olcese C, et al: Relationship between margin width and recurrence of ductal carcinoma in situ: Analysis of 2996 women treated with breast-conserving surgery for 30 years// Ann Surg.-2015.-Vol. 262.-p.623-631.
Wapnir IL, Dignam JJ, Fisher B, et al: Longterm outcomes of invasive ipsilateral breast tumor recurrences after lumpecto- my in NSABP B-17 and B-24 randomized clinical trials for DCIS.//J Natl Cancer Inst.-2011.-Vol. 103.-p.478-488.

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница